Search Results

AOBiome Therapeutics, Inc. (“AOBiome”) today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No. 3132021, with claims focused on its proprietary strain of beneficial AOB, in the class of Nitrosomonas eutropha.

AOBiome Therapeutics, Inc. (“AOBiome”) today announces that The Lancet’s eClinicalMedicine, a peer-reviewed medical journal, has published a report describing the Company’s Phase 2b clinical data for its B244 treatment for mild-to-moderate atopic dermatitis and moderate-to-severe pruritus.

AOBiome Therapeutics, Inc., a leading clinical-stage microbiome company focusing on inflammatory conditions, recently completed a Phase 2b study of 547 patients with moderate-to-severe itch and mild-to-moderate atopic dermatitis.

AOBiome’s 547 subject Phase 2b trial for Treatment of Pruritus (Itch) Associated with Atopic Dermatitis (Eczema) successfully completes its recruitment goal

AOBiome Therapeutics Inc. (“AOB”) announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB’s topical biologic B244 (currently preparing for global Phase 3 clinical trials), a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).

AOBiome Therapeutics, Inc. announced new findings indicating a link between Ammonia Oxidizing Bacteria (AOB) and the human immune system.

AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus and appearance of atopic dermatitis.

AOBiome Therapeutics, Inc., a leading clinical-stage microbiome company focusing on inflammatory conditions, has announced the completion of a cosmetic study investigating the safety and effects of its novel AOB formulation on subjects with mild to moderate eczema.

AOBiome Therapeutics announced the election of Jun Wang, Ph.D., founder and CEO of iCarbonX, as Chairman of AOBiome’s Board of Directors, effective May 31, 2018.

AOBiome Advancing Six Clinical Phase Programs, including Three Trials Testing Its Lead Asset for the Topical Treatment of Eczema, Acne, and Rosacea